Plasmid DNA Manufacturing Market: Current Analysis and Forecast (2024-2032)
Emphasis on Plasmid Grade (Research Grade (RG) Plasmid DNA, High Quality (HQ) Plasmid DNA, Good Manufacturing Practice (GMP) Plasmid DNA), Application (Gene Therapy, DNA Vaccines, Immunotherapy, and Others), Disease Type (Cancer, Infectious Disease, and Others); and Region/Country
Plasmid DNA Manufacturing Market Size & Forecast
The Plasmid DNA Manufacturing Market was valued at approximately USD 521.54 million in 2023 and is expected to grow at a substantial CAGR of around 20.11% during the forecast period (2024-2032) owing to the growing demand for gene therapy and advancements in biotechnology .
Plasmid DNA Manufacturing Market Analysis
Plasmid DNA is described as small, circular, and double helix structures compact molecules of DNA present in bacteria and other microorganisms including yeast. In contrast to chromosomal DNA, plasmids are capable of replication within the cell, and they contain genes that may provide the cell with certain advantages, for instance, genes that give resistance to antibiotics. Such plasmids may be as small as a few thousand base pairs or as large as ten thousand base pairs. They are employed mostly in molecular biology and genetic engineering where researchers manipulate certain genes and place them in plasmids to form recombinant DNA for cloning, gene expression, or protein synthesis.
Increasing prevalence of cancer and infectious diseases, continuous research and development by pharmaceutical companies, along with increased mergers and acquisitions activities to boost manufacturers’ capacities and shares to increase their knowledge of new advancements and technologies, which can enhance the development of plasmid DNA manufacturing’ therapeutics for cancer, HIV and other chronic inflammatory diseases. Moreover, the growing support from the regulatory bodies is further assisting in the significant growth of the plasmid DNA manufacturing market.
Plasmid DNA Manufacturing Market Trends
This section discusses the key market trends influencing the various segments of the plasmid DNA manufacturing market as identified by our research experts.
Shift Towards Personalized Medicine
A key trend that characterizes the market for plasmid DNA manufacturing is the ongoing transition to the era of personalized medicine. Specialized therapies have begun to emerge as healthcare strives to apply treatments according to patients’ needs, arising from patient characteristics. Crucially, plasmid DNA is an essential part of this evolution since it can be used as a delivery tool for genetic material that meets the patient’s needs. This is especially true in areas like gene therapy, where therapies are aimed at the specific genetic variations that lead to diseases. Personalization of medicine is founded on technological progress that may accurately identify individual genetic differences. The development of new therapeutic targets by genomic analysis also demands good quality plasmid DNA that can be efficient in delivering certain genes or RNA sequences. This demand puts pressure on the manufacturing industry as companies look for versatile production systems to handle different plasmid constructs for different applications. Many firms have increased partnerships to bring innovation in personalized medicine.
For instance, in 2020, Ziopharm Oncology, Inc. collaborated with Aldevron to secure rapid neoGMP® plasmid DNA manufacturing for Ziopharm's Sleeping Beauty construct to express TCRs for the treatment of solid tumors.
North America has a significant share of the market in 2023.
The North American plasmid DNA manufacturing is one of the leading markets in the world. This growth is a result of the rising need for gene therapies, genetic vaccines, and better and superior medical treatments, especially for diseases that are becoming more and more dominant throughout the globe. With important investments in biotechnology and a qualified population with adequate access to healthcare services, North America is showing tremendous growth. Additionally, impressive partnerships between market stakeholders and universities are helping to drive innovation further into plasmid-based treatments and vaccines.
Plasmid DNA Manufacturing Market Overview
The Plasmid DNA Manufacturing market is competitive, with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are Charles River Laboratories International, Inc., VGXI, Inc. (GeneOne Life Science), Catalent Inc. (Novo Holdings), Akron Biotech., PlasmidFactory GmbH, DH Life Sciences, LLC, Thermo Fisher Scientific Inc., Lonza, Merck KGaA, GenScript Biotech Corporation.
Plasmid DNA Manufacturing Market News
In October, 2024 - Jinwon Life Science announced that it has signed a $2.7 million plasmid DNA pharmaceutical supply contract with an American bio company. This investment is expected to enhance Jinwon Life Science’s plasmid DNA product portfolio.
In August 2023 - Charles River Laboratories International, Inc., announced a High Quality (HQ) plasmid manufacturing collaboration with Fondazione Telethon. The rare disease organization will leverage Charles River’s market-leading cell and gene contract development and manufacturing organization (CDMO) expertise in high-quality (HQ) plasmid DNA production, and Good Manufacturing Practice- (GMP) compliant plasmid DNA batches to manufacture HQ plasmid DNA for Fondazione Telethon’s lentivirus production that will be used in ex vivo cell and gene therapy.
In February 2023 - BioNTech SE announced the construction completion of the Company’s first proprietary plasmid DNA manufacturing facility in Marburg, Germany. With the new facility, BioNTech plans to independently manufacture plasmid DNA for clinical product candidates and Gene Therapy products in the areas of cancer and infectious diseases. This investment is expected to expand the company’s global reach.
Plasmid DNA Manufacturing Market Report Coverage
Report Attribute | Details |
Base year | 2023 |
Forecast period | 2024-2032 |
Growth momentum | Accelerate at a CAGR of 20.11% |
Market size 2023 | USD 521.54 million |
Regional analysis | North America, Europe, Asia-Pacific, Rest of the World |
Major contributing region | Asia-Pacific is expected to grow at the highest CAGR during the forecasted period. |
Key countries covered | U.S., Canada, Germany, France, UK, Spain, Italy, China, Japan, and India |
Companies profiled | Charles River Laboratories International, Inc., VGXI, Inc. (GeneOne Life Science), Catalent Inc. (Novo Holdings), Akron Biotech., PlasmidFactory GmbH, DH Life Sciences, LLC, Thermo Fisher Scientific Inc., Lonza, Merck KGaA, GenScript Biotech Corporation. |
Report Scope | Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Demand and Supply Side Analysis; Competitive Landscape; Company Profiling |
Segments Covered | By Plasmid grade, Application, By Disease Type, By Region/Country |
Reasons to buy this report:
The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
The report presents a quick review of overall industry performance at one glance.
The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
The study comprehensively covers the market across different segments.
Deep dive regional level analysis of the industry.
Customization Options:
The global Plasmid DNA Manufacturing market can be customized further as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
Research Methodology for the Plasmid DNA Manufacturing Market Analysis (2022-2032)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global plasmid DNA manufacturing market were the three major steps undertaken to create and analyze the penetration of plasmid DNA manufacturing in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global Plasmid DNA Manufacturing market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the plasmid DNA manufacturing market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the plasmid DNA manufacturing market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as plasmid grade, application, disease type, and regions. Further country-level analyses were conducted to evaluate the overall adoption of plasmid DNA manufacturing in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the plasmid DNA manufacturing market. Further, we conducted factor analysis using dependent and independent variables such as plasmid grade, application, disease type, and regions of the plasmid DNA manufacturing market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the plasmid DNA manufacturing market across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global plasmid DNA manufacturing market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2032 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
The industry’s market size, in terms of revenue (USD) and the adoption rate of the plasmid DNA manufacturing market across the major markets domestically.
All percentage shares, splits, and breakdowns of market segments and sub-segments.
Key players in the global plasmid DNA manufacturing market in terms of products offered. Also, the growth strategies adopted by these players to compete in the fast-growing market.
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global plasmid DNA manufacturing market. Data was split into several segments and sub-segments after studying various parameters and trends in the plasmid grade, application, disease type, and regions of the global plasmid DNA manufacturing market.
The main objective of the Global Plasmid DNA Manufacturing Market Study
The current & future market trends of the global plasmid DNA manufacturing market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Analyze the current and forecast market size of the plasmid DNA manufacturing market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments.
Segments in the study include areas of plasmid grade, application, disease type, and regions.
Define and analyze the regulatory framework for the plasmid DNA manufacturing
Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
Analyze the current and forecast market size of the plasmid DNA manufacturing market for the major region.
Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World
Company profiles of the plasmid DNA manufacturing market and the growth strategies adopted by the market players to sustain the fast-growing market.
Deep dive regional level analysis of the industry.
Frequently Asked Questions FAQs
Q1: What is the plasmid DNA manufacturing market's current size and growth potential?
The Plasmid DNA Manufacturing market was valued at USD 521.54 million in 2023 and is expected to grow at a CAGR of 20.11% during the forecast period (2024-2032).
Q2: What are the driving factors for the growth of the plasmid DNA manufacturing market?
The Increasing incidences of cancer and infectious diseases, Innovations in drug delivery technologies, development of combination therapies, supportive regulatory frameworks, and increased research and development drive the plasmid DNA manufacturing market.
Q3: Which segment has the largest share of the plasmid DNA manufacturing market by plasmid grade?
The Good Manufacturing Practice (GMP) plasmid grade segment has the largest share of the plasmid DNA manufacturing market by plasmid grade.
Q4: What are the major trends in the plasmid DNA manufacturing market?
Shift towards personalized medicine and growth of mRNA vaccines are the major trends in the plasmid DNA manufacturing market.
Q5: Which region will dominate the plasmid DNA manufacturing market?
North America dominated the market in 2023.
Related Reports
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
